Bedrijfsoverzicht
Jaguar Health, Inc. is a commercial-stage pharmaceuticals entity dedicated to the development and commercialization of plant-based prescription medicines designed to alleviate gastrointestinal distress in both human and animal populations. The company operates within the broader healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on research and development for potential therapeutic breakthroughs and regulatory approvals. Currently, the firm holds a market capitalization of $4.58M and reports annual revenue of $11.51M, while the specific count of employees is not disclosed in available data. These valuation and revenue figures indicate that Jaguar Health operates as a micro-cap entity with a relatively small financial footprint compared to large-cap pharmaceutical peers, suggesting a high-risk, high-potential profile typical of early-stage biotechnology firms that have yet to achieve significant commercial scalability or profitability.
Financiële gezondheid
The company reported revenue of $11.51M over the trailing twelve months, yet recorded a net income loss of $53.57M and an EBITDA loss of $43.20M, revealing a substantial disparity where operating costs significantly exceed generated revenue. This wide gap between revenue and net income highlights a cost structure characterized by heavy burn rates, likely driven by extensive research, development, and commercialization expenses common in the biotechnology sector. Free cash flow stands at -$15.45M, indicating that the company is consuming its liquid reserves to fund operations and growth initiatives rather than generating surplus capital for reinvestment or distribution. The balance sheet shows a cash position of $968,000 against total debt of $43.61M, creating a scenario where liabilities substantially outweigh available liquid assets. The debt-to-equity ratio is not disclosed, but the disparity between cash and debt suggests a leveraged balance sheet that could strain the company under adverse market conditions or increased borrowing costs. The current ratio is 0.50, which signifies that for every dollar of current liabilities, the company holds only fifty cents in current assets, pointing to potential short-term liquidity challenges. Return on Equity is not available for calculation, but the return on assets is -61.5%, demonstrating that the company's assets are generating negative returns on an annualized basis.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable due to the lack of earnings, while the forward P/E is listed at -0.06, reflecting the expectation of continued negative earnings in the near term. A negative forward P/E typically implies that analysts or the market anticipate the company will remain unprofitable, preventing traditional earnings-based valuation multiples from being meaningful. The price-to-book ratio is 0.43, indicating that the market values the company at less than half of its book value, which often occurs when market participants discount assets that may not be easily liquidatable or when future cash flows are viewed as highly uncertain. The price-to-sales ratio stands at 0.40 and the EV/EBITDA is -1.12, providing alternative valuation perspectives that rely on revenue multiples or enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though the negative EV/EBITDA reinforces the company's current loss-making status. The stock has traded between a 52-week low of $0.31 and a high of $15.48, meaning the current price sits significantly below the recent peak, reflecting substantial volatility and a wide trading range typical of low-liquidity micro-cap stocks. The beta is not disclosed, so a direct comparison to broader market volatility cannot be quantified based on the available data.
Growth & Income
Revenue growth year-over-year is -7.8%, while earnings growth is not applicable due to the company's consistent losses, indicating that the business is contracting in terms of top-line sales rather than expanding its market share or product uptake. The absence of positive earnings growth relative to revenue highlights the difficulty in scaling a commercial-stage pharmaceutical company without achieving profitability first. As a non-dividend payer, the company does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, as the firm must reinvest any available resources or raise capital to sustain its operations and fund its pipeline. Consequently, the overall growth and income profile is defined by capital depletion and top-line contraction, with no current mechanism for generating shareholder income through dividends or capital appreciation relative to the recent 52-week high.